Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.44 | N/A | +1.84% |
management commentary, guidance changes, and full analysis available with Pro.
| +1.84% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting operational efficiency as a priority. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on maintaining operational efficiency.
This earnings report shows that Johnson & Johnson was able to exceed EPS expectations, indicating strong performance in that area. However, the lack of revenue data and guidance may leave investors uncertain about the company's future direction. The stock reaction is not available, which could suggest limited immediate market response to these results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PINNACLE FINL PARTNE
Apr 15, 2013